457947-61-4

Upstream product

• 20896-27-9 methyl 4-amino-5-chloro-2-methoxybenzoate 
• 4093-31-6 methyl 2-methoxy 4-acetamido 5-chloro benzoate 
• 126463-85-2 4-acetylamino-5-chloro-2-methoxy-3-nitro-benzoic acid methyl ester 

Downstream Products

• 1312608-71-1 C₄₂H₅₁N₉O₇ 
• 1312610-74-4 C₃₈H₄₅N₇O₅ 
• 1312610-73-3 C₃₆H₄₅N₇O₅ 
• 1312610-72-2 C₃₆H₄₂ClN₇O₇ 
• 1312610-71-1 C₃₇H₄₄ClN₇O₇ 
• 1312610-70-0 C₃₇H₄₄ClN₃O₁₃ 
• 1312610-62-0 C₄₃H₄₈ClN₃O₁₃ 
• 1312610-61-9 C₂₃H₁₆Br₂ClNO₅ 
• 1312611-72-5 C₂₁H₁₂Cl₃NO₅ 
• 1312610-60-8 C₂₁H₁₄ClNO₇ 
• 1312610-59-5 C₂₃H₁₈ClNO₇ 
• 1312610-56-2 C₉H₇BrClNO₅ 
• 1279088-66-2 (1-{4-[6-oxo-8-phenyl-1-(2-trimethylsilanyl-ethoxymethyl)-1,6-dihydro-chromeno[7,8-d]imidazol-7-yl]-phenyl}-cyclobutyl)-carbamic acid tert-butyl ester 
• 1279088-67-3 (1-{4-[6-oxo-8-phenyl-3-(2-trimethylsilanyl-ethoxymethyl)-3,6-dihydro-chromeno[7,8-d]imidazol-7-yl]-phenyl}-cyclobutyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

ORGANIC COMPOUNDS

Compounds of formula (I) in free or salt form, where Y, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the CXCR2 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Alternative heterocycles for DNA recognition

Methods and compositions are provided for forming complexes between dsDNA and novel oligomers comprising fused six-membered rings. By appropriate choice of target sequences and oligomers, complexes comprising oligomer-DNA are obtained with high association constants. The formation of complexes can be used for identification of specific dsDNA sequences, for inhibiting gene transcription, and as a therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific genes.

NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY

A compound of the formula (I): wherein Z4, Z5 and Z9 each is independently carbon atom or nitrogen atom; Y is hydroxy, mercapto or amino; RA is a group of the formula: (wherein C ring is nitrogen-containing heteroaryl) has an inhibitory activity against integrase.

Imidazopyridine/pyrrole and hydroxybenzimidazole/pyrrole pairs for DNA minor groove recognition

The DNA binding properties of fused heterocycles imidazo[4,5-b]pyridine (Ip) and hydroxybenzimidazole (Hz) paired with pyrrole (Py) in eight-ring hairpin polyamides are reported. The recognition profile of Ip/Py and Hz/Py pairs were compared to the five-m